Absent in melanoma 2 enhances anti‐tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer

Conditionally replicative adenoviruses (CRAds) were promising approach for solid tumour treatment, but its oncolytic efficiency and toxicity are still not satisfactory for further clinical application. Here, we developed the CAIX promotor (CAIX^promotor)‐controlled CRAd armed with a tumour suppressor absent in melanoma 2 (AIM2) to enhance its oncolytic potency. The CAIX^promotor‐AIM2 adenoviruses (Ad‐CAIX^promotor‐AIM2) could efficiently express E1A and AIM2 in renal cancer cells. Compared with Ad‐CAIX^promotor, Ad‐CAIX^promotor‐AIM2 significantly inhibited cell proliferation and enhanced cell apoptosis and cell killing, thus resulting in the oncolytic efficiency in 786‐O cells or OSRC‐2 cells. To explore the therapeutic effect, various Ads were intratumourally injected into OSRC‐2‐xenograft mice. The tumour growth was remarkably inhibited in Ad‐CAIX^promotor‐AIM2‐treated group as demonstrated by reduced tumour volume and weight with a low toxicity. The inflammasome inhibitor YVAD‐CMK resulted in the reduction of anti‐tumour activity by Ad‐CAIX^promotor‐AIM2 in vitro or in vivo, suggesting that inflammasome activation response was required for the enhanced therapeutic efficiency. Furthermore, lung metastasis of renal cancer mice was also suppressed by Ad‐CAIX^promotor‐AIM2 treatment accompanied by the decreased tumour fossil in lung tissues. These results indicated that the tumour‐specific Ad‐CAIX^promotor‐AIM2 could be applied for human renal cancer therapy. The therapeutic strategy of AIM2‐based CRAds could be a potential and promising approach for the therapy of primary solid or metastasis tumours.     

Membrane‐Free Zn/MnO2 Flow Battery for Large‐Scale Energy Storage

The traditional Zn/MnO₂ battery has attracted great interest due to its low cost, high safety, high output voltage, and environmental friendliness. However, it remains a big challenge to achieve long‐term stability, mainly owing to the poor reversibility of the cathode reaction. Different from previous studies where the cathode redox reaction of MnO₂/MnOOH is in solid state with limited reversibility, here a new aqueous rechargeable Zn/MnO₂ flow battery is constructed with dissolution–precipitation reactions in both cathodes (Mn²⁺/MnO₂) and anodes (Zn²⁺/Zn), which allow mixing of anolyte and catholyte into only one electrolyte and remove the requirement for an ion selective membrane for cost reduction. Impressively, this new battery exhibits a high discharge voltage of ≈1.78 V, good rate capability (10C discharge), and excellent cycling stability (1000 cycles without decay) at the areal capacity ranging from 0.5 to 2 mAh cm^‐2. More importantly, this battery can be readily enlarged to a bench scale flow cell of 1.2 Ah with good capacity retention of 89.7% at the 500th cycle, displaying great potential for large‐scale energy storage.     

Interface Engineering of Hierarchical Branched Mo‐Doped Ni3S2/NixPy Hollow Heterostructure Nanorods for Efficient Overall Water Splitting

Rational design and construction of bifunctional electrocatalysts with excellent activity and durability is imperative for water splitting. Herein, a novel top‐down strategy to realize a hierarchical branched Mo‐doped sulfide/phosphide heterostructure (Mo‐Ni₃S₂/Ni_xP_y hollow nanorods), by partially phosphating Mo‐Ni₃S₂/NF flower clusters, is proposed. Benefitting from the optimized electronic structure configuration, hierarchical branched hollow nanorod structure, and abundant heterogeneous interfaces, the as‐obtained multisite Mo‐Ni₃S₂/Ni_xP_y/NF electrode has remarkable stability and bifunctional electrocatalytic activity in the hydrogen evolution reaction (HER)/oxygen evolution reaction (OER) in 1 m KOH solutions. It possesses an extremely low overpotential of 238 mV at the current density of 50 mA cm^?2 for OER. Importantly, when assembled as anode and cathode simultaneously, it merely requires an ultralow cell voltage of 1.46 V to achieve the current density of 10 mA cm^?2, with excellent durability for over 72 h, outperforming most of the reported Ni‐based bifunctional materials. Density functional theory results further confirm that the doped heterostructure can synergistically optimize Gibbs free energies of H and O‐containing intermediates (OH*, O*, and OOH*) during HER and OER processes, thus accelerating the catalytic kinetics of electrochemical water splitting. This work demonstrates the importance of the rational combination of metal doping and interface engineering for advanced catalytic materials.     

Atomically Dispersed Mo Supported on Metallic Co9S8 Nanoflakes as an Advanced Noble‐Metal‐Free Bifunctional Water Splitting Catalyst Working in Universal pH Conditions

Water splitting requires development of cost‐effective multifunctional materials that can catalyze both the hydrogen evolution reaction (HER) and the oxygen evolution reaction (OER) efficiently. Currently, the OER relies on the noble‐metal catalysts; since with other catalysts, its operation environment is greatly limited in alkaline conditions. Herein, an advanced water oxidation catalyst based on metallic Co₉S₈ decorated with single‐atomic Mo (0.99 wt%) is synthesized (Mo‐Co₉S₈@C). It exhibits pronounced water oxidization activity in acid, alkali, and neutral media by showing positive onset potentials of 200, 90, and 290 mV, respectively, which manifests the best Co₉S₈‐based single‐atom Mo catalyst till now. Moreover, it also demonstrates excellent HER performance over a wide pH range. Consequently, the catalyst even outperforms noble metal Pt/IrO₂‐based catalysts for overall water splitting (only requiring 1.68 V in acid, and 1.56 V in alkaline). Impressively, it works under a current density of 10 mA cm^?2 with no obvious decay during a 24 h (0.5 m H₂SO₄) and 72 h (1.0 m KOH) durability experiment. Density functional theory (DFT) simulations reveal that the synergistic effects of atomically dispersed Mo with Co‐containing substrates can efficiently alter the binding energies of adsorbed intermediate species and decrease the overpotentials of the water splitting.     

Distinct controls over the temporal dynamics of soil carbon fractions after land use change

Soil organic carbon (SOC), the largest terrestrial carbon pool, plays a significant role in soil‐related ecosystem services such as climate regulation, soil fertility and agricultural production. However, its fate under land use change is difficult to predict. A major issue is that SOC comprised of numerous organic compounds with potentially distinct and poorly understood turnover properties. Here we use spatiotemporal measurements of the particulate (POC), mineral‐associated (MOC) and charred SOC (COC) fractions from 176 trials involving changes in land use to assess their underlying controls. We find that the initial pool sizes of each of the three fractions consistently and dominantly control their temporal dynamics after changes in land use (i.e. the baseline effects). The effects of climate, soil physicochemical properties and plant residues, however, are fraction‐ and time‐dependent. Climate and soil properties show similar importance for controlling the dynamics of MOC and COC, while plant residue inputs (in term of their quantity and quality) are much less important. For POC, plant residues and management practices (e.g. the frequency of pasture in crop‐pasture rotation systems) are substantially more important, overriding the influence of climate. These results demonstrate the pivotal role of measuring SOC composition and considering fraction‐specific stabilization and destabilization processes for effective SOC management and reliable SOC predictions.     

New insights into small‐cell lung cancer development and therapy

Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first‐line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.